Stock Track | Aurinia Pharmaceuticals Soars 5.20% in Pre-market on Strong Q4 Earnings Beat and Robust Guidance

Stock Track02-26

Aurinia Pharmaceuticals' stock surged 5.20% during Thursday's pre-market session following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.

The biopharmaceutical company reported quarterly earnings of $1.53 per diluted share, a massive increase from $0.01 per share a year earlier and well above the consensus estimate of approximately $0.21 to $0.26. Total revenue for the quarter reached $77.1 million, beating estimates and representing a 29% year-over-year increase, driven by strong demand for its lupus nephritis drug LUPKYNIS, whose net product sales grew 29% to $74.2 million.

Furthermore, Aurinia provided optimistic guidance for 2026, projecting total revenue between $315 million and $325 million. The company also highlighted its solid financial position, including a cash balance of $398.0 million and a share repurchase program, alongside progress in its clinical pipeline, including plans to advance studies for its drug candidate aritinercept.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166641625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166641625","market":"hk","top_or_hot":-1,"title":"Stock Track | Aurinia Pharmaceuticals Soars 5.20% in Pre-market on Strong Q4 Earnings Beat and Robust Guidance","media":"Stock Track","content":"<p>Aurinia Pharmaceuticals' stock surged 5.20% during Thursday's pre-market session following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.</p><p>The biopharmaceutical company reported quarterly earnings of $1.53 per diluted share, a massive increase from $0.01 per share a year earlier and well above the consensus estimate of approximately $0.21 to $0.26. Total revenue for the quarter reached $77.1 million, beating estimates and representing a 29% year-over-year increase, driven by strong demand for its lupus nephritis drug LUPKYNIS, whose net product sales grew 29% to $74.2 million.</p><p>Furthermore, Aurinia provided optimistic guidance for 2026, projecting total revenue between $315 million and $325 million. The company also highlighted its solid financial position, including a cash balance of $398.0 million and a share repurchase program, alongside progress in its clinical pipeline, including plans to advance studies for its drug candidate aritinercept.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Aurinia Pharmaceuticals Soars 5.20% in Pre-market on Strong Q4 Earnings Beat and Robust Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Aurinia Pharmaceuticals Soars 5.20% in Pre-market on Strong Q4 Earnings Beat and Robust Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aurinia Pharmaceuticals' stock surged 5.20% during Thursday's pre-market session following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.</p><p>The biopharmaceutical company reported quarterly earnings of $1.53 per diluted share, a massive increase from $0.01 per share a year earlier and well above the consensus estimate of approximately $0.21 to $0.26. Total revenue for the quarter reached $77.1 million, beating estimates and representing a 29% year-over-year increase, driven by strong demand for its lupus nephritis drug LUPKYNIS, whose net product sales grew 29% to $74.2 million.</p><p>Furthermore, Aurinia provided optimistic guidance for 2026, projecting total revenue between $315 million and $325 million. The company also highlighted its solid financial position, including a cash balance of $398.0 million and a share repurchase program, alongside progress in its clinical pipeline, including plans to advance studies for its drug candidate aritinercept.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"","article_id":"1166641625","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166641625","pubTimestamp":1772106405,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Aurinia Pharmaceuticals' stock surged 5.20% during Thursday's pre-market session following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"个股追踪|Aurinia Pharmaceuticals盘前飙升5.20%，因第四季度盈利强劲增长和强劲指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1},"content_text":"Aurinia Pharmaceuticals' stock surged 5.20% during Thursday's pre-market session following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.The biopharmaceutical company reported quarterly earnings of $1.53 per diluted share, a massive increase from $0.01 per share a year earlier and well above the consensus estimate of approximately $0.21 to $0.26. Total revenue for the quarter reached $77.1 million, beating estimates and representing a 29% year-over-year increase, driven by strong demand for its lupus nephritis drug LUPKYNIS, whose net product sales grew 29% to $74.2 million.Furthermore, Aurinia provided optimistic guidance for 2026, projecting total revenue between $315 million and $325 million. The company also highlighted its solid financial position, including a cash balance of $398.0 million and a share repurchase program, alongside progress in its clinical pipeline, including plans to advance studies for its drug candidate aritinercept.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166641625","isCrawlerRequest":true}